Acumen Pharmaceuticals Inc (ABOS) Stock Price, Quote & News

Company Profile

Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops targeted therapies for the treatment of Alzheimer's disease. It focuses on advancing a targeted immunotherapy drug candidate, sabirnetug (ACU193), which is in its Phase 2 ALTITUDE-AD clinical trial to target toxic soluble amyloid beta oligomers. Acumen Pharmaceuticals, Inc. has a collaboration and license agreement with Halozyme, Inc. for the development of a subcutaneous formulation of Sabirnetug, as well as with...

Industry: Biotechnology

Sector: Healthcare

Phone: 617 344 4190

Website: acumenpharm.com

Address:

1210-1220 Washington St., Suite 210, Newton, United States

Johndoe456 Jun. 30 at 1:08 AM

$ABOS

0 · Reply

SannieVerraderlijk Jun. 19 at 5:58 AM

$ABOS $CCCC $NKTR $RLMD $ SABS $ ZURA Some longs added to Russell 3000 yesterday

0 · Reply

focafoca99 Jun. 17 at 4:53 PM

$ABOS captured a strategic partnership as Acumen exercised its exclusive option to develop Alzheimer’s therapies using J‑Brain Cargo

0 · Reply

LibertarianTreehugger Jun. 16 at 2:14 PM

Acumen Advances Two New Alzheimer's Drug Candidates Designed to Reach the Brain More Effectively: https://jlsfund.substack.com/p/acumen-advances-two-new-alzheimers $ABOS

0 · Reply

DARKP00L Jun. 16 at 1:25 PM

$ABOS 07:43 on Jun. 16 2026 Acumen Pharmaceuticals Nominates Two Development Candidates In Its Enhanced Brain Delivery Program For Alzheimer's Disease Treatments, IND Submission Expected In Mid-2027 #tradeideas

0 · Reply

focafoca99 Jun. 16 at 11:41 AM

$ABOS announces nomination of two enhanced brain delivery candidates for Alzheimer’s disease under its JCR collaboration.

0 · Reply

Stock_Catcher Jun. 16 at 11:30 AM

$ABOS Acumen Pharmaceuticals Announces Nomination of Two Enhanced Brain Delivery™ (EBD™) Development Candidates for the Treatment of Alzheimer’s Disease

0 · Reply

Mitersaw1 May. 21 at 9:49 PM

$ABOS

0 · Reply

Mitersaw1 May. 20 at 9:52 PM

$ABOS

0 · Reply

Stockley_Bulbousberries May. 20 at 7:00 PM

$ABOS

0 · Reply

JCR Pharmaceuticals Announces That Acumen Pharmaceuticals Has Exercised its Exclusive Option to Develop Therapeutic Candidates for Alzheimer's Disease, Enabled by J-Brain Cargo® Technology Platform

2026-06-16T11:41:31.000Z - 14 days ago

Acumen nominates two development candidates in EBD program

Jun 16, 2026, 7:30 AM EDT - 14 days ago

Acumen Pharmaceuticals Announces Nomination of Two Enhanced Brain Delivery™ (EBD™) Development Candidates for the Treatment of Alzheimer's Disease

May 14, 2026, 11:55 AM EDT - 6 weeks ago

Acumen Pharmaceuticals Transcript: Bank of America Global Healthcare Conference 2026

May 12, 2026, 8:00 AM EDT - 7 weeks ago

Acumen Pharmaceuticals Earnings Call Transcript: Q1 2026

May 12, 2026, 8:00 AM EDT - 7 weeks ago

Acumen Pharmaceuticals Earnings release: Q1 2026

May 12, 2026, 8:00 AM EDT - 7 weeks ago

Acumen Pharmaceuticals Quarterly report: Q1 2026

May 12, 2026, 7:00 AM EDT - 7 weeks ago

Acumen Pharmaceuticals Reports First Quarter 2026 Financial Results and Business Highlights

May 12, 2026, 7:00 AM EDT - 7 weeks ago

Acumen Pharmaceuticals Slides: Corporate presentation

May 7, 2026, 4:00 PM EDT - 7 weeks ago

Acumen Pharmaceuticals to Participate in the Bank of America Securities 2026 Health Care Conference

May 5, 2026, 4:00 PM EDT - 7 weeks ago

Acumen Pharmaceuticals to Report First Quarter Financial Results on May 12, 2026

Apr 23, 2026, 8:00 AM EDT - 2 months ago

Acumen Pharmaceuticals Proxy statement: Proxy filing

Apr 23, 2026, 8:00 AM EDT - 2 months ago

Acumen Pharmaceuticals Proxy statement: Proxy filing

2026-03-26T20:35:57.000Z - 3 months ago

Acumen files to sell 10.83M shares of common stock for holders

Mar 26, 2026, 8:00 AM EDT - 3 months ago

Acumen Pharmaceuticals Earnings Call Transcript: Q4 2025

Mar 26, 2026, 8:00 AM EDT - 3 months ago

Acumen Pharmaceuticals Annual report: Q4 2025

Mar 26, 2026, 8:00 AM EDT - 3 months ago

Acumen Pharmaceuticals Earnings release: Q4 2025

Mar 26, 2026, 8:00 AM EDT - 3 months ago

Acumen Pharmaceuticals Registration statement: Registration filing

Mar 26, 2026, 7:00 AM EDT - 3 months ago

Acumen Pharmaceuticals Reports Financial Results for the Year Ended December 31, 2025 and Business Highlights

Mar 26, 2026, 7:00 AM EDT - 3 months ago

Acumen Pharmaceuticals Slides: Corporate presentation

Mar 19, 2026, 4:00 PM EDT - 3 months ago

Acumen Pharmaceuticals to Report Fourth Quarter and Year-End 2025 Financial Results on March 26, 2026

Mar 18, 2026, 11:00 AM EDT - 3 months ago

Acumen Pharmaceuticals Transcript: Stifel 2026 Virtual CNS Forum

2026-03-17T12:11:29.000Z - 3 months ago

Acumen announces new research findings at Alzheimer’s and Parkinson’s conference

2026-03-17T09:55:29.000Z - 3 months ago

Acumen price target raised to $8 from $7 at BTIG

2026-03-16T10:45:28.000Z - 3 months ago

Acumen announces $35.75M private placement

Mar 16, 2026, 6:30 AM EDT - 3 months ago

Acumen Pharmaceuticals Announces $35.75 Million Private Placement to Advance Potential Best-in-Class Molecules from Amyloid Beta Oligomer-Selective Enhanced Brain Delivery Portfolio

Mar 10, 2026, 4:00 PM EDT - 3 months ago

Acumen Pharmaceuticals to Participate in the Stifel 2026 Virtual CNS Forum

2026-01-27T12:26:49.000Z - 5 months ago

Acumen price target raised to $7 from $4 at BTIG

BIIB

2025-12-17T12:16:58.000Z - 6 months ago

Acumen initiated with a Buy at Lucid Capital

2025-12-02T13:05:54.000Z - 7 months ago

Acumen announces new research at CTAD on ACU193

2025-11-18T14:44:09.000Z - 7 months ago

Acumen price target lowered to $8 from $9 at BofA

2025-11-17T13:20:29.000Z - 8 months ago

Acumen first participant dosed in OLE portion of Phase 2 ALTITUDE-AD trial

Nov 12, 2025, 8:00 AM EST - 8 months ago

Acumen Pharmaceuticals Earnings Call Transcript: Q3 2025

Nov 12, 2025, 8:00 AM EST - 8 months ago

Acumen Pharmaceuticals Quarterly report: Q3 2025

Nov 12, 2025, 8:00 AM EST - 8 months ago

Acumen Pharmaceuticals Earnings release: Q3 2025

Nov 11, 2025, 4:40 PM EST - 8 months ago

Acumen Pharmaceuticals Transcript: Stifel 2025 Healthcare Conference

Nov 11, 2025, 7:00 AM EST - 8 months ago

Acumen Pharmaceuticals Slides: Corporate Presentation

2025-11-10T13:25:50.000Z - 8 months ago

Acumen appoints George Golumbeski as chairman of the board

2025-10-16T11:45:46.000Z - 9 months ago

Acumen price target lowered to $4 from $11 at BTIG

Sep 5, 2025, 9:10 AM EDT - 10 months ago

Acumen Pharmaceuticals Transcript: Cantor Global Healthcare Conference 2025

Sep 2, 2025, 3:15 PM EDT - 10 months ago

Acumen Pharmaceuticals Transcript: Citi's Biopharma Back to School Conference

Aug 26, 2025, 4:00 PM EDT - 10 months ago

Acumen Pharmaceuticals to Participate in Upcoming Investor Conferences

2025-08-25T11:10:41.000Z - 11 months ago

Acumen price target lowered to $9 from $10 at BofA

Aug 12, 2025, 8:00 AM EDT - 11 months ago

Acumen Pharmaceuticals Earnings Call Transcript: Q2 2025

Aug 12, 2025, 8:00 AM EDT - 11 months ago

Acumen Pharmaceuticals Quarterly report: Q2 2025

Aug 12, 2025, 8:00 AM EDT - 11 months ago

Acumen Pharmaceuticals Earnings release: Q2 2025

Aug 12, 2025, 7:00 AM EDT - 11 months ago

Acumen Pharmaceuticals Reports Second Quarter 2025 Financial Results and Business Highlights

Aug 11, 2025, 8:00 AM EDT - 11 months ago

Acumen Pharmaceuticals Slides: Corporate Presentation

Aug 5, 2025, 4:00 PM EDT - 11 months ago

Acumen Pharmaceuticals to Report Second Quarter 2025 Financial Results on August 12, 2025

Jul 15, 2025, 7:00 AM EDT - 1 year ago

JCR Pharmaceuticals and Acumen Pharmaceuticals Announce Collaboration to Develop Therapy for Alzheimer's Disease, Enabled by J-Brain Cargo® Technology Platform

Jul 10, 2025, 8:00 AM EDT - 1 year ago

Acumen Pharmaceuticals to Present Studies on Cost Savings Associated with Use of pTau217 Screening Assay in Phase 2 ALTITUDE-AD Study and Sabirnetug Oligomer-Selectivity at the Alzheimer's Association International Conference (AAIC®) 2025

May 14, 2025, 11:15 AM EDT - 1 year ago

Acumen Pharmaceuticals Transcript: BofA Securities 2025 Healthcare Conference

May 13, 2025, 8:00 AM EDT - 1 year ago

Acumen Pharmaceuticals Earnings Call Transcript: Q1 2025

May 13, 2025, 8:00 AM EDT - 1 year ago

Acumen Pharmaceuticals Quarterly report: Q1 2025

May 13, 2025, 8:00 AM EDT - 1 year ago

Acumen Pharmaceuticals Earnings release: Q1 2025

May 13, 2025, 7:00 AM EDT - 1 year ago

Acumen Pharmaceuticals Slides: Corporate Presentation

May 7, 2025, 4:00 PM EDT - 1 year ago

Acumen Pharmaceuticals to Participate in the Bank of America Healthcare Conference

May 6, 2025, 4:00 PM EDT - 1 year ago

Acumen Pharmaceuticals to Report First Quarter 2025 Financial Results on May 13, 2025

Apr 23, 2025, 8:00 AM EDT - 1 year ago

Acumen Pharmaceuticals Proxy statement: Proxy Filing

Apr 23, 2025, 8:00 AM EDT - 1 year ago

Acumen Pharmaceuticals Proxy statement: Proxy Filing

Apr 2, 2025, 7:00 AM EDT - 1 year ago

Acumen Pharmaceuticals Showcases pTau217 Trial Screening Progress in Phase 2 ALTITUDE-AD Trial and Preclinical Research Methods at AD/PD 2025 and AAN Annual Meeting

Mar 27, 2025, 8:00 AM EDT - 1 year ago

Acumen Pharmaceuticals Earnings Call Transcript: Q4 2024

Mar 27, 2025, 8:00 AM EDT - 1 year ago

Acumen Pharmaceuticals Annual report: Q4 2024

Mar 27, 2025, 8:00 AM EDT - 1 year ago

Acumen Pharmaceuticals Earnings release: Q4 2024

Mar 27, 2025, 8:00 AM EDT - 1 year ago

Acumen Pharmaceuticals Slides: Q4 2024

Mar 20, 2025, 4:00 PM EDT - 1 year ago

Acumen Pharmaceuticals to Report Fourth Quarter and Year-End 2024 Financial Results on March 27, 2025

Mar 18, 2025, 3:30 PM EDT - 1 year ago

Acumen Pharmaceuticals Transcript: Stifel’s 2025 Virtual CNS Forum

Mar 18, 2025, 8:48 AM EDT - 1 year ago

Acumen Pharmaceuticals CEO Discusses Novel Targeted Therapies for Alzheimer's

Mar 17, 2025, 12:30 PM EDT - 1 year ago

Acumen Pharmaceuticals Transcript: UBS Virtual CNS Day 2025

Mar 12, 2025, 8:00 AM EDT - 1 year ago

Acumen Pharmaceuticals to Present During International Conference on Alzheimer's and Parkinson's Diseases 2025 and American Academy of Neurology Annual Meeting

Dec 3, 2024, 3:00 PM EST - 1 year ago

Acumen Pharmaceuticals Transcript: 7th Annual Evercore ISI HealthCONx Healthcare Conference

Nov 26, 2024, 4:00 PM EST - 1 year ago

Acumen Pharmaceuticals to Participate in the 7th Annual Evercore ISI HealthCONx Conference

Nov 18, 2024, 1:15 PM EST - 1 year ago

Acumen Pharmaceuticals Transcript: Stifel 2024 Healthcare Conference

Nov 13, 2024, 4:15 PM EST - 1 year ago

Acumen Pharmaceuticals Transcript: UBS Global Healthcare Conference 2024

Nov 12, 2024, 8:00 AM EST - 1 year ago

Acumen Pharmaceuticals Earnings Call Transcript: Q3 2024

Nov 12, 2024, 8:00 AM EST - 1 year ago

Acumen Pharmaceuticals Quarterly report: Q3 2024

Nov 12, 2024, 8:00 AM EST - 1 year ago

Acumen Pharmaceuticals Earnings release: Q3 2024

Nov 12, 2024, 8:00 AM EST - 1 year ago

Acumen Pharmaceuticals Slides: Q3 2024

Nov 11, 2024, 4:00 PM EST - 1 year ago

Acumen Pharmaceuticals to Participate in the Stifel Healthcare Conference

Nov 6, 2024, 4:00 PM EST - 1 year ago

Acumen Pharmaceuticals to Participate in the UBS Global Healthcare Conference

Oct 31, 2024, 8:05 AM EDT - 1 year ago

Acumen Pharmaceuticals Presents Innovative Trial Screening Advancements Utilizing pTau217 Assay in Phase 2 Study of Sabirnetug for Early Alzheimer's Disease at the 17th Annual Clinical Trials on Alzheimer's Disease Conference

Oct 23, 2024, 8:00 AM EDT - 1 year ago

Acumen Pharmaceuticals to Deliver Late-Breaking Presentation at 17th Annual Clinical Trials on Alzheimer's Disease (CTAD) Conference

Oct 15, 2024, 8:00 AM EDT - 1 year ago

Lucy Therapeutics Appoints Kim Drapkin as Board Chair

LENZ

Oct 7, 2024, 8:00 AM EDT - 1 year ago

Acumen Pharmaceuticals Transcript: Bank of America CNS Therapeutics Virtual Conference

Oct 2, 2024, 10:00 AM EDT - 1 year ago

Acumen Pharmaceuticals Transcript: R&D Day 2024

Oct 2, 2024, 10:00 AM EDT - 1 year ago

Acumen Pharmaceuticals Slides: FY 2024

Sep 30, 2024, 4:00 PM EDT - 1 year ago

Acumen Pharmaceuticals to Participate in the Bank of America CNS Therapeutics Virtual Conference

Sep 25, 2024, 4:00 PM EDT - 1 year ago

Acumen Pharmaceuticals to Host Virtual R&D Day on Oct. 2, 2024

Sep 10, 2024, 1:30 PM EDT - 1 year ago

Acumen Pharmaceuticals Transcript: H.C. Wainwright 26th Annual Global Investment Conference 2024

Sep 3, 2024, 4:00 PM EDT - 1 year ago

Acumen Pharmaceuticals to Participate in the H.C. Wainwright 26th Annual Global Investor Conference

Aug 13, 2024, 8:00 AM EDT - 2 years ago

Acumen Pharmaceuticals Earnings Call Transcript: Q2 2024

Aug 13, 2024, 8:00 AM EDT - 2 years ago

Acumen Pharmaceuticals Quarterly report: Q2 2024

Aug 13, 2024, 8:00 AM EDT - 2 years ago

Acumen Pharmaceuticals Earnings release: Q2 2024

Aug 13, 2024, 8:00 AM EDT - 2 years ago

Acumen Pharmaceuticals Slides: Q2 2024

Aug 6, 2024, 4:00 PM EDT - 2 years ago

Acumen Pharmaceuticals to Report Second Quarter Results on August 13, 2024

Jul 29, 2024, 7:00 AM EDT - 2 years ago

Acumen Pharmaceuticals Announces First Subject Dosed in Phase 1 Study of Subcutaneous Sabirnetug (ACU193) for Early Alzheimer's Disease

Jul 28, 2024, 7:30 AM EDT - 2 years ago

Acumen Pharmaceuticals Presents Patient Experience and Biomarker Data from Phase 1 INTERCEPT-AD Study at the Alzheimer's Association International Conference (AAIC®) 2024

May 20, 2024, 12:30 PM EDT - 2 years ago

Acumen Pharmaceuticals Transcript: H.C. Wainwright 2nd Annual BioConnect Investor Conference at NASDAQ

May 15, 2024, 11:55 AM EDT - 2 years ago

Acumen Pharmaceuticals Transcript: BofA Securities 2024 Health Care Conference

May 14, 2024, 8:00 AM EDT - 2 years ago

Acumen Pharmaceuticals Earnings Call Transcript: Q1 2024

May 14, 2024, 8:00 AM EDT - 2 years ago

Acumen Pharmaceuticals Quarterly report: Q1 2024

May 14, 2024, 8:00 AM EDT - 2 years ago

Acumen Pharmaceuticals Earnings release: Q1 2024

May 14, 2024, 7:00 AM EDT - 2 years ago

Acumen Pharmaceuticals Reports First Quarter 2024 Financial Results and Business Highlights

May 14, 2024, 7:00 AM EDT - 2 years ago

Acumen Pharmaceuticals Slides: Corporate Presentation

May 13, 2024, 4:00 PM EDT - 2 years ago

Acumen Pharmaceuticals to Participate in the H.C. Wainwright 2nd Annual BioConnect Investor Conference

May 8, 2024, 5:47 PM EDT - 2 years ago

Acumen Pharmaceuticals to Participate in the 2024 Bank of America Healthcare Conference

May 8, 2024, 8:00 AM EDT - 2 years ago

Acumen Pharmaceuticals Announces First Patient Dosed in ALTITUDE-AD, a Phase 2 Clinical Trial of Sabirnetug (ACU193) in Early Alzheimer's Disease

May 7, 2024, 4:00 PM EDT - 2 years ago

Acumen Pharmaceuticals to Report First Quarter Results on May 14, 2024

Apr 22, 2024, 8:00 AM EDT - 2 years ago

Acumen Pharmaceuticals Proxy statement: Proxy Filing

Apr 22, 2024, 8:00 AM EDT - 2 years ago

Acumen Pharmaceuticals Proxy statement: Proxy Filing

Apr 16, 2024, 8:00 AM EDT - 2 years ago

Acumen Pharmaceuticals Presents First Comprehensive Clinical and Biomarker Data for Sabirnetug (ACU193) at American Academy of Neurology 2024 Annual Meeting

Apr 4, 2024, 8:00 AM EDT - 2 years ago

Acumen Pharmaceuticals Collaborates with Lonza to Advance Sabirnetug for the Treatment of Alzheimer's Disease

Mar 27, 2024, 8:00 AM EDT - 2 years ago

Acumen Pharmaceuticals Registration statement: Registration Filing

Mar 26, 2024, 8:00 AM EDT - 2 years ago

Acumen Pharmaceuticals Earnings Call Transcript: Q4 2023

Mar 26, 2024, 8:00 AM EDT - 2 years ago

Acumen Pharmaceuticals Annual report: Q4 2023

Mar 26, 2024, 8:00 AM EDT - 2 years ago

Acumen Pharmaceuticals Earnings release: Q4 2023

Mar 26, 2024, 7:00 AM EDT - 2 years ago

Acumen Pharmaceuticals Reports Financial Results for the Year Ended December 31, 2023 and Business Highlights

Mar 19, 2024, 4:00 PM EDT - 2 years ago

Acumen Pharmaceuticals to Report Fourth Quarter and Year-End 2023 Financial Results on March 26, 2024

Mar 19, 2024, 12:00 PM EDT - 2 years ago

Acumen Pharmaceuticals Transcript: Stifel Virtual 2024 CNS Day

Mar 18, 2024, 1:18 PM EDT - 2 years ago

Acumen Pharmaceuticals Slides: Corporate Presentation

Mar 12, 2024, 4:00 PM EDT - 2 years ago

Acumen Pharmaceuticals to Participate in the Stifel 2024 CNS Days

Mar 8, 2024, 1:41 PM EST - 2 years ago

Acumen Pharmaceuticals Slides: Investor Presentation

Mar 8, 2024, 8:50 AM EST - 2 years ago

Acumen Pharmaceuticals Presents Sabirnetug (ACU193) Fluid Biomarker and Target Engagement Analyses from Phase 1 INTERCEPT-AD Study in Early Alzheimer's at the AD/PD™ 2024 Annual Meeting

Feb 21, 2024, 8:00 AM EST - 2 years ago

Acumen Pharmaceuticals to Present Sabirnetug (ACU193) Fluid Biomarker and Target Engagement Analyses from Phase 1 INTERCEPT-AD Study in Early Alzheimer's at the AD/PD™ 2024 Annual Meeting

Feb 1, 2024, 7:00 AM EST - 2 years ago

Acumen Pharmaceuticals Appoints Dr. James Doherty as President and Chief Development Officer

Jan 11, 2024, 1:30 PM EST - 2 years ago

Acumen Pharmaceuticals Transcript: J.P. Morgan 42nd Annual Healthcare Conference 2024

Jan 11, 2024, 1:30 PM EST - 2 years ago

Acumen Pharmaceuticals Slides: FY 2024

Jan 4, 2024, 4:15 PM EST - 2 years ago

Acumen Pharmaceuticals to Present at the 42nd Annual J.P. Morgan Healthcare Conference

Nov 13, 2023, 8:00 AM EST - 2 years ago

Acumen Pharmaceuticals Earnings Call Transcript: Q3 2023

Nov 13, 2023, 8:00 AM EST - 2 years ago

Acumen Pharmaceuticals Quarterly report: Q3 2023

Nov 13, 2023, 8:00 AM EST - 2 years ago

Acumen Pharmaceuticals Earnings release: Q3 2023

Nov 13, 2023, 8:00 AM EST - 2 years ago

Acumen Pharmaceuticals Slides: Q3 2023

Nov 13, 2023, 7:00 AM EST - 2 years ago

Acumen Pharmaceuticals Secures $50.0 Million Credit Facility with K2 HealthVentures

Nov 13, 2023, 7:00 AM EST - 2 years ago

Acumen Pharmaceuticals Reports Third Quarter 2023 Financial Results and Business Highlights

Nov 9, 2023, 10:00 AM EST - 2 years ago

Acumen Pharmaceuticals Transcript: UBS Biopharma Conference 2023

Nov 6, 2023, 4:01 PM EST - 2 years ago

Acumen Pharmaceuticals to Report Third Quarter Financial Results on November 13, 2023

Nov 6, 2023, 7:30 AM EST - 2 years ago

Acumen Pharmaceuticals, Inc. and Halozyme Enter Global Collaboration and License Agreement to Develop Subcutaneous Formulation of ACU193 with ENHANZE® Technology

Johndoe456 Jun. 30 at 1:08 AM

$ABOS

0 · Reply

SannieVerraderlijk Jun. 19 at 5:58 AM

$ABOS $CCCC $NKTR $RLMD $ SABS $ ZURA Some longs added to Russell 3000 yesterday

0 · Reply

focafoca99 Jun. 17 at 4:53 PM

$ABOS captured a strategic partnership as Acumen exercised its exclusive option to develop Alzheimer’s therapies using J‑Brain Cargo

0 · Reply

LibertarianTreehugger Jun. 16 at 2:14 PM

Acumen Advances Two New Alzheimer's Drug Candidates Designed to Reach the Brain More Effectively: https://jlsfund.substack.com/p/acumen-advances-two-new-alzheimers $ABOS

0 · Reply

DARKP00L Jun. 16 at 1:25 PM

0 · Reply

focafoca99 Jun. 16 at 11:41 AM

$ABOS announces nomination of two enhanced brain delivery candidates for Alzheimer’s disease under its JCR collaboration.

0 · Reply

Stock_Catcher Jun. 16 at 11:30 AM

$ABOS Acumen Pharmaceuticals Announces Nomination of Two Enhanced Brain Delivery™ (EBD™) Development Candidates for the Treatment of Alzheimer’s Disease

0 · Reply

Mitersaw1 May. 21 at 9:49 PM

$ABOS

0 · Reply

Mitersaw1 May. 20 at 9:52 PM

$ABOS

0 · Reply

Stockley_Bulbousberries May. 20 at 7:00 PM

$ABOS

0 · Reply

Mitersaw1 May. 15 at 9:18 PM

$ABOS

0 · Reply

SuperGreenToday May. 15 at 7:23 AM

$ABOS Share Price: $2.39 Contract Selected: Oct 16, 2026 $2.5 Calls Buy Zone: $0.68 – $0.84 Target Zone: $1.30 – $1.58 Potential Upside: 80% ROI Time to Expiration: 153 Days | Updates via https://fxcapta.com/stockinfo/

0 · Reply

jacksparo May. 13 at 7:48 PM

$SLS $IBRX $OCGN $ABOS $CADL Turned on my newly created A. I want to see how it will perform from now till 08:00 PM US ET. I spent almost 12 days trying to finish it using level 2 and 3 algorithmic data coding! Hopefully it will help me in my fight against the filthy shorts!

0 · Reply

SannieVerraderlijk May. 13 at 10:19 AM

$ABOS 50M EV for Alzheimer candidate with decent scientific rationale, likely will run up a lot into data eoy, upside is too skewed not to

0 · Reply

Mitersaw1 May. 12 at 7:24 PM

$ABOS

0 · Reply

MarketBeat May. 12 at 1:09 PM

https://marketbeat.com/a/8650490/ $ABOS Acumen Pharmaceuticals Q1 Earnings Call Highlights

0 · Reply

EarningsInsider May. 12 at 12:46 PM

https://www.marketbeat.com/earnings/reports/2026-5-12-acumen-pharmaceuticals-inc-stock/ $ABOS Acumen Pharmaceuticals Earnings Transcript

0 · Reply

StocktwitsEarnings May. 12 at 12:35 PM

$ABOS Q1 '26 Earnings Results & Recap • Reported GAAP EPS of -$0.33 up 31.25% YoY • Acumen Pharmaceuticals expects topline results for its ALTITUDE-AD Phase 2 study in late 2026, and its cash balance of $128.4M is expected to support operations into early 2027.

0 · Reply

BillionerOfKing Apr. 29 at 5:10 PM

$ABOS Current Stock Price: $2.37 Contracts to trade: $2.5 ABOS May 15 2026 Call Entry: $0.46 Exit: $0.71 ROI: 55% Hold ~29 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts

0 · Reply

Adamchristlover Apr. 22 at 10:39 PM

$CRBU $HUMA $ABOS Nice seeing you Jack I am holding HUMA and CRBU

0 · Reply

jacksparo Apr. 22 at 5:36 PM

$CRBU From my email and it’s doing good so far since then $HUMA In my Live Biotech group still holding some . $ABOS Still holding!

0 · Reply

Market Cap	170.46M
Revenue (ttm)	0.00
Net Income (ttm)	-121.34M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.35

Volume	851,700
Avg Vol	462,902
Day's Range	N/A - N/A
Shares Out	72.23M
Stochastic %K	97%
Beta	0.34
Analysts	Strong Sell
Price Target	$7.50